BUZZ-Vir Biotechnology shares rise after appointing Sawaf from Theravance as Chief Financial Officer

October 1 - ** Vir Biotechnology (VIR.O) shares rose more than 3% in afternoon trading to $11.53

** The company appointed Aziz Sawaf as Chief Financial Officer, effective October 5

** Aziz previously worked at Theravance Biopharma, serving as Chief Financial Officer since 2023

** He will succeed former Chief Financial Officer Jason O'Byrne, who left on August 3 to pursue new opportunities

** According to data compiled by London Stock Exchange Group (LSEG), all 10 analysts covering VIR are bullish, with a median target price of $20

** Including the day's movement, the stock is up 91% so far this year

(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may be incorrect or fail to include necessary context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation function.)